<DOC>
	<DOCNO>NCT01121939</DOCNO>
	<brief_summary>The purpose Phase II trial define activity VEGF inhibitor bevacizumab , HER1/HER2 inhibitor pertuzumab , sandostatin patient advance neuroendocrine cancer . In particular , efficacy bevacizumab pertuzumab treatment great interest . The primary endpoint trial response rate . Toxicity progression-free survival obtain evaluate .</brief_summary>
	<brief_title>Combination Bevacizumab , Pertuzumab , Sandostatin Adv . Neuroendocrine Cancers</brief_title>
	<detailed_description>- To determine overall response rate patient low grade neuroendocrine cancer treat combination bevacizumab , pertuzumab sandostatin LAR® . - To determine disease control rate ( objective response + stable disease ) , time treatment progression , progression-free survival , overall survival patient advance low grade neuroendocrine cancer treat bevacizumab , pertuzumab Sandostatin LAR® treatment . - To define toxicity safety combination bevacizumab , pertuzumab Sandostatin LAR® use patient advance low grade neuroendocrine cancer .</detailed_description>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Patients biopsyproven advance , unresectable metastatic , welldifferentiated ( lowgrade ) neuroendocrine carcinoma , include typical carcinoid , pancreatic islet cell welldifferentiated neuroendocrine carcinoma . 2 . Patients document evidence disease progression . 3 . Patients currently receive previously treat single agent Sandostatin LAR® eligible . 4 . Patients must &gt; =1 unidimensional measurable lesion definable MRI CT scan . Disease must measurable per RECIST version 1.1 criterion . 5 . Left Ventricular Ejection Fraction ( LVEF ) &gt; =50 % determine either ECHO MUGA &lt; =6 week prior study entry . 6 . An ECOG Performance Status 02 . 7 . Laboratory value follow : ANC &gt; =1500/μL Hgb &gt; =9 g/dL Platelets &gt; =100,000/μL AST/SGOT &lt; =2.5 x ULN &lt; =5.0 x ULN patient liver metastasis ALT/SGPT &lt; =2.5 x ULN &lt; =5.0 x ULN patient liver metastasis Bilirubin &lt; =1.5 x ULN Creatinine &lt; =2.0 mg/dL calculate creatinine clearance &gt; =50 mL/min 8 . Patients &gt; =18 year age . 9 . Patients must life expectancy &gt; 12 week . 10 . Patient must accessible treatment followup . 11 . Women childbearing potential must negative serum urine pregnancy test perform &lt; =7 day prior start treatment . Women childbearing potential must use effective birth control measure treatment . If woman become pregnant suspect pregnant participate study , must agree inform treat physician immediately . 12 . Patients must able understand nature study give write informed consent , comply study requirement 1 . Patients poorly differentiate neuroendocrine carcinoma , highgrade neuroendocrine carcinoma , adenocarcinoid , goblet cell carcinoid , atypical carcinoid , anaplastic carcinoid , small cell carcinoma eligible . 2 . Previous treatment VEGF EGFR inhibitor . 3 . Cytotoxic chemotherapy , immunotherapy radiotherapy &lt; =4 week prior study entry . 4 . History know presence central nervous system ( CNS ) metastases . 5 . Patients major surgical procedure ( include mediastinoscopy ) , open biopsy , significant traumatic injury &lt; =4 week prior begin treatment . 6 . Female patient pregnant lactate . 7 . History hypersensitivity active inactive excipients component treatment ( bevacizumab , sandostatin , and/or pertuzumab ) . 8 . Patients proteinuria screen demonstrated urine dipstick proteinuria &gt; =2+ ( patient discover &gt; =2+ proteinuria dipstick urinalysis baseline undergo 24hour urine collection , must demonstrate &lt; =1 g protein/24 hour eligible ) . 9 . Patients serious nonhealing wound , active ulcer , untreated bone fracture . 10 . Patients evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) . 11 . Patients history hematemesis hemoptysis ( define bright red blood ½ teaspoon per episode ) &lt; =1 month prior study enrollment . 12 . History myocardial infarction unstable angina &lt; =6 month prior begin treatment . 13 . Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg /or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) . Initiation antihypertensive agent permit provided adequate control document least 1 week prior Day study treatment . 14 . New York Heart Association ( NYHA ) grade II great congestive heart failure ( CHF ) . 15 . Serious cardiac arrhythmia require medication . 16 . Significant vascular disease ( e.g. , aortic aneurysm require surgical repair , recent peripheral arterial thrombosis ) &lt; =6 month prior Day 1 treatment . 17 . History stroke transient ischemic attack &lt; =6 month prior begin treatment . 18 . Any prior history hypertensive crisis hypertensive encephalopathy . 19 . History abdominal fistula gastrointestinal perforation &lt; =6 month prior Day 1 begin treatment . 20 . Concurrent severe , intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . 21 . Any known positive test human immunodeficiency virus , hepatitis C virus acute chronic hepatitis B infection . 22 . Mental condition would prevent patient comprehension nature , risk associate , study . 23 . Use nonapproved investigational agent &lt; =28 day prior administration first dose study drug . Patients may receive investigational anticancer treatment participate study . 24 . Past current history neoplasm entry diagnosis exception treat nonmelanoma skin cancer carcinoma situ cervix , cancer cure local therapy alone DFS &gt; =5 year . 25 . Infection require IV antibiotic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>advanced neuroendocrine</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Pertuzumab</keyword>
	<keyword>Omnitarg</keyword>
	<keyword>2C4</keyword>
	<keyword>Sandostatin</keyword>
	<keyword>Octreotide</keyword>
</DOC>